Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) today. The company’s shares closed last Friday at $1.58.
According to TipRanks, Knickerbocker is a 4-star analyst with an average return of 9.6% and a 45.16% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Xtant Medical Holdings, Fennec Pharmaceuticals, and scPharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xeris Pharmaceuticals with a $5.50 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $3.07 and a one-year low of $0.97. Currently, Xeris Pharmaceuticals has an average volume of 923K.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XERS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals (XERS) Company Description:
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
Read More on XERS:
